Taken together, these results indicate that PPARγ agonist treatment improved several metabolic disorders independently of adipose tissue function in aKO mice, suggesting that HMGCR-mediated lipodystrophy was minimally associated with the deficiency of MVA-derivative PPARγ ligands. Here, PPARG is linked to lipodystrophy.